Major Investor Quietly Boosts Position in InMed Pharmaceuticals
TipRanks (Wed, 16-Sep 10:02 PM ET)
Mentari’s $200 Million Private Placement and Merger with InMed Signal Ambitious Clinical Push
Market Chameleon (Wed, 22-Jul 5:53 AM ET)
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
PRNewswire (Wed, 22-Jul 7:00 AM ET)
Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 6-Jul 7:15 PM ET)
PRNewswire (Mon, 6-Jul 2:18 PM ET)
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Inmed Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol INM.
As of September 16, 2026, INM stock price was flat at $1.28 with 19,644 million shares trading.
INM has a beta of 2.27, meaning it tends to be more sensitive to market movements. INM has a correlation of 0.05 to the broad based SPY ETF.
INM has a market cap of $7.03 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, INM traded as high as $41.60 and as low as $.58.
INM has underperformed the market in the last year with a price return of -42.3% while the SPY ETF gained +15.2%. INM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.2% and -3.0%, respectively, while the SPY returned +0.1% and -1.0%, respectively.
INM support price is $1.21 and resistance is $1.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INM shares will trade within this expected range on the day.